|Articles|July 13, 2020

COVID-19 Disruption of Trials is in Decline

Most disruptions to clinical trials over the past three months were caused by the suspension of enrollment, followed by slow enrollment, and delayed initiation, says GlobalData, a data and analytics company. The number of disrupted trials began to fall between June and July.

For more information, click here.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Articles

Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
Phase IV Trial Shows Strong Immune Response from Moderna’s Updated Spikevax Against LP.8.1 Variant of COVID-19
September 17th 2025
Generative AI Transforms Clinical Study Report Development
September 16th 2025
Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success
September 16th 2025

Trending on Applied Clinical Trials Online

Generative AI Transforms Clinical Study Report Development

Why Clinical Trials Are at a Crossroads and How Site Networks Are the Key to Success

IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes

Everything to Know About FDA’s Push Towards Radical Transparency in 2025

Phase IV Trial Shows Strong Immune Response from Moderna’s Updated Spikevax Against LP.8.1 Variant of COVID-19

© 2025 MJH Life Sciences^®

All rights reserved.